Ascletis Pharma's oral GLP-1 drug ASC30 shows 6.2% placebo-adjusted weight loss in Phase 1b obesity trial, matching Roche's ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Maine state officials on Tuesday reported new cases of bird flu in wild birds and urged precautions to protect chickens and other domestic birds. Avian influenza has been detected in "four Canada ...

Bosnia has reported an outbreak of highly pathogenic H5N1 avian influenza, the World Organisation for Animal Health said on Tuesday, as a seasonal wave of the disease known as bird flu continues in ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 This proposed transaction further diversifies Zimm ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...